Health
STEP 2 shows benefits of higher semaglutide dose in type 2 diabetes – medwireNews
The STEP 2 trial shows that overweight or obese people with type 2 diabetes achieve greater weight loss and larger improvements in cardiometabolic risk factors…
medwireNews: The STEP 2 trial shows that overweight or obese people with type 2 diabetes achieve greater weight loss and larger improvements in cardiometabolic risk factors when given a higher semaglutide dose than is currently approved.
Improvements in glycemic control were relatively small, with glycated hemoglobin (HbA1c) levels falling by an average of 1.6% (17.5 mmol/mol) among people randomly assigned to receive weekly semaglutide 2.4 mg for 68 weeks and 1.5% (15.9 mmol/mol) among those given…
-
General17 hours agoMore buses without dedicated lanes likely after Gold Coast light rail plan scrapped
-
Business23 hours agoBuy this monthly high-yield ETF instead
-
Business21 hours agoThis artificial intelligence (AI) stock could be the Nvidia of quantum computing
-
Business21 hours agoTesla just offered Elon Musk $1 trillion. Here’s what it could mean for the company.